BETA DRUGS
|
BETA DRUGS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 41.10 | 42.02 | 37.90 | 31.95 | 25.82 |
| CEPS(Rs) | 57.84 | 54.42 | 45.79 | 40.74 | 31.78 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 241.46 | 195.25 | 163.43 | 127.82 | 96.05 |
| Tax Rate(%) | 23.74 | 25.54 | 25.26 | 25.18 | 27.62 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 19.67 | 20.59 | 20.29 | 23.39 | 23.23 |
| EBIT Margin(%) | 18.11 | 17.65 | 17.44 | 19.14 | 19.69 |
| Pre Tax Margin(%) | 14.13 | 15.72 | 16.49 | 18.08 | 18.66 |
| PAT Margin (%) | 10.78 | 11.71 | 12.32 | 13.53 | 13.51 |
| Cash Profit Margin (%) | 15.24 | 15.16 | 15.63 | 18.11 | 17.45 |
| Performance Ratios | |||||
| ROA(%) | 8.77 | 11.99 | 15.63 | 16.74 | 17.53 |
| ROE(%) | 18.78 | 23.95 | 26.03 | 28.55 | 30.85 |
| ROCE(%) | 19.16 | 25.23 | 32.74 | 33.94 | 36.38 |
| Asset Turnover(x) | 0.81 | 1.02 | 1.27 | 1.24 | 1.30 |
| Sales/Fixed Asset(x) | 2.22 | 2.83 | 2.83 | 2.50 | 2.57 |
| Working Capital/Sales(x) | 1.70 | 1.66 | 3.17 | 3.51 | 3.83 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.45 | 0.35 | 0.35 | 0.40 | 0.39 |
| Receivable days | 105.14 | 91.57 | 87.61 | 86.71 | 78.48 |
| Inventory Days | 63.66 | 55.19 | 49.64 | 42.67 | 38.24 |
| Payable days | 161.92 | 139.01 | 121.55 | 124.66 | 101.32 |
| Valuation Parameters | |||||
| PER(x) | 28.94 | 45.35 | 31.00 | 19.62 | 21.90 |
| PCE(x) | 20.56 | 35.02 | 25.66 | 14.65 | 16.95 |
| Price/Book(x) | 4.93 | 9.76 | 7.55 | 4.90 | 5.89 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 3.19 | 5.28 | 3.96 | 2.66 | 2.98 |
| EV/Core EBITDA(x) | 14.14 | 23.62 | 19.10 | 11.21 | 12.59 |
| EV/EBIT(x) | 17.62 | 29.93 | 22.73 | 13.89 | 15.11 |
| EV/CE(x) | 3.13 | 5.71 | 6.82 | 4.22 | 4.84 |
| M Cap / Sales | 3.13 | 5.31 | 4.01 | 2.65 | 2.96 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 6.20 | 22.54 | 30.21 | 23.54 | 58.31 |
| Core EBITDA Growth(%) | 7.18 | 32.08 | 13.87 | 23.99 | 72.14 |
| EBIT Growth(%) | 8.99 | 24.01 | 18.64 | 20.08 | 97.06 |
| PAT Growth(%) | -2.21 | 16.42 | 18.62 | 23.73 | 111.76 |
| EPS Growth(%) | -2.20 | 10.87 | 18.62 | 23.73 | 111.76 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.60 | 0.70 | 0.09 | 0.17 | 0.22 |
| Current Ratio(x) | 2.96 | 2.92 | 1.99 | 1.93 | 1.87 |
| Quick Ratio(x) | 2.32 | 2.39 | 1.55 | 1.49 | 1.47 |
| Interest Cover(x) | 4.55 | 9.15 | 18.29 | 18.00 | 19.06 |
| Total Debt/Mcap(x) | 0.12 | 0.07 | 0.01 | 0.03 | 0.04 |
Compare Financial Ratios of peers of BETA DRUGS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BETA DRUGS | ₹2,187.8 Cr | 12.6% | -5% | -2.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹420,831.0 Cr | -0.4% | -6.1% | 5.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹242,074.0 Cr | 0.9% | -3.3% | 39.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹175,355.0 Cr | 0.1% | -7.2% | 28.2% | Stock Analytics | |
| CIPLA | ₹107,439.0 Cr | -0.3% | -4% | -15.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,417.0 Cr | 1.5% | 3.1% | 0.4% | Stock Analytics | |
BETA DRUGS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BETA DRUGS | 12.6% |
-5% |
-2.7% |
| SENSEX | 0.6% |
-1.4% |
-10.7% |
You may also like the below Video Courses